Apellis Pharmaceuticals (NASDAQ:APLS) Receives “Outperform” Rating from Robert W. Baird

Robert W. Baird reiterated their outperform rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS) in a research report report published on Friday morning, Benzinga reports. Robert W. Baird currently has a $100.00 target price on the stock.

A number of other research analysts have also weighed in on APLS. Needham & Company LLC reissued a buy rating and issued a $85.00 target price on shares of Apellis Pharmaceuticals in a research note on Wednesday, May 8th. HC Wainwright reiterated a buy rating and issued a $92.00 target price on shares of Apellis Pharmaceuticals in a report on Tuesday, May 28th. JPMorgan Chase & Co. boosted their price target on shares of Apellis Pharmaceuticals from $78.00 to $79.00 and gave the stock an overweight rating in a research note on Wednesday, March 6th. Wedbush dropped their price target on shares of Apellis Pharmaceuticals from $67.00 to $57.00 and set a neutral rating for the company in a research note on Wednesday, April 17th. Finally, Mizuho dropped their target price on Apellis Pharmaceuticals from $60.00 to $52.00 and set a neutral rating on the stock in a report on Monday, April 29th. Four equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Apellis Pharmaceuticals presently has an average rating of Moderate Buy and a consensus target price of $75.56.

Apellis Pharmaceuticals Price Performance

NASDAQ:APLS opened at $36.29 on Friday. The stock has a market capitalization of $4.40 billion, a PE ratio of -10.49 and a beta of 0.95. Apellis Pharmaceuticals has a 52 week low of $19.83 and a 52 week high of $91.35. The stock’s 50-day moving average price is $42.37 and its 200-day moving average price is $54.60. The company has a quick ratio of 3.02, a current ratio of 3.77 and a debt-to-equity ratio of 0.35.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.54) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.54). The firm had revenue of $172.33 million for the quarter, compared to analyst estimates of $163.37 million. Apellis Pharmaceuticals had a negative net margin of 79.67% and a negative return on equity of 160.77%. Apellis Pharmaceuticals’s quarterly revenue was up 284.3% compared to the same quarter last year. During the same period last year, the company posted ($1.56) EPS. As a group, equities analysts expect that Apellis Pharmaceuticals will post -1.1 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Pascal Deschatelets sold 78,907 shares of the business’s stock in a transaction dated Wednesday, May 8th. The shares were sold at an average price of $42.35, for a total value of $3,341,711.45. Following the completion of the sale, the insider now owns 1,115,983 shares of the company’s stock, valued at approximately $47,261,880.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director A. Sinclair Dunlop sold 37,000 shares of the business’s stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $39.24, for a total transaction of $1,451,880.00. Following the sale, the director now owns 136,998 shares in the company, valued at $5,375,801.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Pascal Deschatelets sold 78,907 shares of the business’s stock in a transaction that occurred on Wednesday, May 8th. The shares were sold at an average price of $42.35, for a total transaction of $3,341,711.45. Following the sale, the insider now owns 1,115,983 shares in the company, valued at approximately $47,261,880.05. The disclosure for this sale can be found here. Insiders have sold 185,014 shares of company stock valued at $8,537,118 in the last quarter. Company insiders own 6.80% of the company’s stock.

Institutional Trading of Apellis Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in shares of Apellis Pharmaceuticals by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 9,555,678 shares of the company’s stock worth $572,003,000 after buying an additional 85,701 shares during the period. Price T Rowe Associates Inc. MD increased its position in Apellis Pharmaceuticals by 38.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,460,339 shares of the company’s stock valued at $147,277,000 after acquiring an additional 677,098 shares in the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of Apellis Pharmaceuticals by 109.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 2,145,004 shares of the company’s stock valued at $128,400,000 after purchasing an additional 1,121,497 shares during the last quarter. Polar Capital Holdings Plc boosted its stake in shares of Apellis Pharmaceuticals by 126.6% in the 3rd quarter. Polar Capital Holdings Plc now owns 1,053,875 shares of the company’s stock valued at $40,089,000 after purchasing an additional 588,875 shares during the last quarter. Finally, Norges Bank bought a new position in Apellis Pharmaceuticals during the 4th quarter worth approximately $56,640,000. 96.29% of the stock is owned by institutional investors.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).